Investor
Deep Track Capital, LP
CIK 0001856083 · filed 2026-05-15 · SEC filing
13F book
$6.12B
Positions
62
16 new · 7 sold
Largest name
5.0%
Guardant Health, Inc. · GH
Est. mark
−$149.6M
Price effect on 46 names still held. Flow $612.1M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Guardant Health, Inc. | GH | 3.34M | $308.4M | 5.0% | −$27.4M | Added$22.4M |
| Immunovant, Inc. | IMVT | 11.5M | $286.3M | 4.7% | −$6.69M | Held |
| Tarsus Pharmaceuticals, Inc. | TARS | 3.6M | $252.5M | 4.1% | −$35.2M | Added$6.57M |
| Vaxcyte, Inc. | PCVX | 4.3M | $249.9M | 4.1% | $47.9M | Added$65.3M |
| Structure Therapeutics Inc. | GPCR | 4.28M | $206.3M | 3.4% | −$87.8M | Added−$79.7M |
| Axsome Therapeutics, Inc. | AXSM | 1.1M | $185.9M | 3.0% | −$15M | Cut−$24.1M |
| Apellis Pharmaceuticals Inc | — | 4.53M | $182.3M | 3.0% | $68.5M | Cut−$12.3M |
| Ocular Therapeutix, Inc | OCUL | 19.7M | $166.7M | 2.7% | −$29.6M | Added$68.8M |
| Vera Therapeutics, Inc. | VERA | 4.11M | $165.2M | 2.7% | −$29.4M | Added$22.3M |
| Alumis Inc. | ALMS | 6.77M | $149.2M | 2.4% | — | New |
| Ionis Pharmaceuticals Inc | IONS | 1.95M | $146.4M | 2.4% | −$6.83M | Added$11.9M |
| Nuvalent Inc | — | 1.38M | $141M | 2.3% | — | New |
| Alkermes plc. | ALKS | 3.59M | $127M | 2.1% | $14.8M | Added$71M |
| Centessa Pharmaceuticals Plc | — | 3.16M | $125.4M | 2.0% | $29.4M | Added$75.4M |
| Moonlake Immunotherapeutics | MLTX | 6.41M | $119.5M | 2.0% | $25.2M | Added$58.7M |
| Maze Therapeutics, Inc. | MAZE | 3.48M | $103.8M | 1.7% | −$40.3M | Cut−$72.1M |
| Oruka Therapeutics, Inc. | ORKA | 2.03M | $99.8M | 1.6% | $38.1M | Cut$34.3M |
| Nurix Therapeutics, Inc. | NRIX | 6.35M | $98.4M | 1.6% | −$22M | Cut−$35.1M |
| Genmab A/S | — | 3.66M | $98.3M | 1.6% | — | New |
| Cytokinetics Inc | CYTK | 1.37M | $90.6M | 1.5% | $3.26M | Cut−$121.5M |
| GRAIL, Inc. | GRAL | 1.72M | $89M | 1.5% | −$34.7M | Added$1.49M |
| Lb Pharmaceuticals Inc | LBRX | 3.35M | $82.7M | 1.4% | $8.05M | Held |
| MBX Biosciences, Inc. | MBX | 2.76M | $82.3M | 1.3% | −$4.66M | Cut−$20.2M |
| Bicara Therapeutics Inc. | BCAX | 4.06M | $80.8M | 1.3% | $8M | Added$36.8M |
| Compass Pathways Plc | CMPS | 12.2M | $67.3M | 1.1% | −$10M | Added$16.6M |
| Biomarin Pharmaceutical Inc | BMRN | 1.15M | $65M | 1.1% | −$3.38M | Cut−$71.7M |
| BridgeBio Pharma, Inc. | BBIO | 841.4K | $62.5M | 1.0% | −$1.81M | Added$517.9K |
| Immunocore Hldgs Plc | — | 1.93M | $58.2M | 1.0% | −$8.81M | Cut−$11.3M |
| Tango Therapeutics, Inc. | TNGX | 2.75M | $57.5M | 0.9% | $29.6M | Added$35.8M |
| Definium Therape | DFTX | 3M | $56.7M | 0.9% | — | New |
| Terns Pharmaceuticals Inc | — | 1.07M | $56.6M | 0.9% | $9.47M | Added$25.5M |
| Geron Corp | GERN | 31.7M | $47.3M | 0.8% | $5.39M | Cut$4.35M |
| Ani Pharmaceuticals Inc | ANIP | 600K | $46.1M | 0.8% | −$974.5K | Added$8.43M |
| CorMedix Inc. | CRMD | 6.27M | $42.6M | 0.7% | −$25.5M | Added−$18.7M |
| Ataibeckley Inc Com Shs | ATAI | 12M | $42.5M | 0.7% | — | New |
| Celldex Therapeutics Inc New | — | 1.28M | $40.7M | 0.7% | $5.85M | Cut−$10.9M |
| Cogent Biosciences, Inc. | COGT | 1M | $38.5M | 0.6% | $1.35M | Added$22.4M |
| Corvus Pharmaceuticals, Inc. | CRVS | 2.49M | $36.5M | 0.6% | — | New |
| Dyne Therapeutics, Inc. | DYN | 2M | $36.3M | 0.6% | −$2.86M | Cut−$15.6M |
| Soleno Therapeutics Inc | — | 1.08M | $36.1M | 0.6% | −$12.8M | Added−$10.2M |
| Aclaris Therapeutics, Inc. | ACRS | 9.35M | $35M | 0.6% | — | New |
| Veradermics, Inc | MANE | 500K | $31.6M | 0.5% | — | New |
| Verastem, Inc. | VSTM | 5.74M | $30.4M | 0.5% | −$13.9M | Held |
| Engene Holdings Inc | — | 4.38M | $29.8M | 0.5% | −$9.72M | Held |
| Viridian Therapeutics Inc | — | 1.39M | $27.3M | 0.4% | −$16.1M | Cut−$51.3M |
| X4 Pharmaceuticals, Inc | XFOR | 6.34M | $26.2M | 0.4% | $651.8K | Added$6.13M |
| Solid Biosciences Inc. | SLDB | 3.57M | $25.7M | 0.4% | — | New |
| Enanta Pharmaceuticals Inc | ENTA | 1.96M | $24.7M | 0.4% | −$6.14M | Held |
| Apogee Therapeutics, Inc. | APGE | 285K | $24M | 0.4% | — | New |
| Kura Oncology, Inc. | KURA | 2.64M | $21.5M | 0.4% | — | New |
| Century Therapeutics, Inc. | IPSC | 9.49M | $21.4M | 0.4% | — | New |
| Beam Therapeutics Inc. | BEAM | 820.8K | $19.6M | 0.3% | — | New |
| Context Therapeutics Inc. | CNTX | 7.42M | $19.4M | 0.3% | $8.53M | Held |
| Personalis, Inc. | PSNL | 3M | $19.1M | 0.3% | — | New |
| Janux Therapeutics, Inc. | JANX | 1.19M | $16.5M | 0.3% | $8.96K | Added$15.3M |
| ProMIS Neurosciences Inc. | PMN | 835.7K | $10.6M | 0.2% | — | New |
| Crescent Biopharma, Inc. | CBIO | 453.7K | $8.33M | 0.1% | $2.95M | Held |
| Inventiva Sa | — | 1.22M | $6.78M | 0.1% | $441K | Added$4.51M |
| Larimar Therapeutics, Inc. | LRMR | 1.5M | $6.75M | 0.1% | — | New |
| Cybin Inc. | HELP | 1.31M | $6.3M | 0.1% | −$4.44M | Cut−$8.86M |
| BillionToOne, Inc. | BLLN | 50K | $3.95M | 0.1% | −$145K | Held |
| Aligos Therapeutics, Inc. | ALGS | 444.1K | $3.3M | 0.1% | −$839.4K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.